
MACROGENICS INC
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
MacroGenics is a biopharmaceutical company that develops antibody-based therapeutics for cancer treatment, using proprietary technology platforms to engineer bispecific antibodies and other immune-targeting molecules. Its pipeline includes margetuximab and other product candidates in various stages of clinical development, often advanced through partnerships with larger pharmaceutical companies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Peters Jeffrey StuartSenior VP, GC, and Secretary | Sell | $129K | 31,105at $4.15 | Aug 19, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable MGNX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.